Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis

ABSTRACT

The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.

CROSS-REFERENCES TO RELATED APPLICATIONS

This is a divisional of U.S. patent application Ser. No. 09/853,581,filed May 14, 2001, which is a divisional of U.S. patent applicationSer. No. 08/933,359, filed Sep. 18, 1997, now abandoned. Each of theabove-noted applications is incorporated herein in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a composition and method for treating humansand animals for neoplastic or cancerous growths as well as treating suchpatients in order to restore or boost hematopoiesis. The composition ofthe present invention comprises a combination of a cytotoxicT-lymphocyte inducing composition and an agent which is capable ofneutralizing or down regulating the activity of tumor secretedimmunosuppressive factors.

2. Description of the Related Art

Cytotoxic T-lymphocytes (CTLs) are believed to be the major hostmechanism in response to a variety of viral infections and neoplastic orcancerous growth (Greenberg et al., Adv. Immunol., 49:281-355 (1991);Baxevanis et al., Crit. Rev. Oncol.-Hematol., 16:157-79 (1994); Ward etal., Biological Approaches to Cancer Treatment, Biomodulation, pp.72-97, edited by M. S. Mitchel, New York: McGraw Hill, Inc. (1993)).These cells eliminate infected or transformed cells by recognizingantigen fragments in association with various molecules (termed class IMHC molecules) on the infected or transformed cells (Baxevanis et al.,Crit. Rev. Oncol-Hematol., 16:157-79 (1994); Matsumura et al., Science,257:927-34 (1992); Long et al., Immunol. Today, 10:232-34 (1989)).

The use of soluble forms of tumor associated antigens (TAA) in subunitvaccines to stimulate tumor specific T-cell immunity is a desirablestrategy for developing a safe and effective immunotherapy for cancers.The advantage of using whole protein is that after antigen processing inspecialized antigen presenting cells (APC) it contains the entirerepertoire of potential peptide epitopes. However, the immunization withwhole soluble antigen generally does not activate CTLs. Therefore, tostimulate CTL response to specific protein antigens, various approachesfocusing on improving the intracellular antigen delivery to APC havebeen tried. These include live viral (Moss, B., Science, 252: 1662-67(1991); Takahashi et al., PNAS USA, 85:3105-09 (1988)) and bacterial(Aldovini et al., Nature (London), 351:479-482 (1991); Sadoff et al.,Science, 240:336-38 (1988)) vectors, non-replicating plasmid DNAinoculation (Ulmer et al., Science, 259:1745-49 (1993)), conjugation ofprotein and peptides to lipophilic compounds (Deres et al., Nature(London), 342:561-64 (1989)) or ISCOM (Takahashi et al., Nature(London), 344:873-75 (1990)). The major concerns for vaccines, based onviral vectors or DNA injections, are safety relating to possible DNAintegration into the host cell genome which is particularly relevant tooncogenes with transforming potentials and the induction of anti-vectorresponse in vivo. Furthermore, in immunocompromised individuals, it issafer to use purified antigens in combination with an appropriatenon-infectious delivery system with minimal toxicity to induce an immuneresponse.

A safe and advantageous composition by which CTL response may be inducedin humans and domesticated or agriculturally important animals andincludes the whole soluble protein in a non-infectious delivery systemwas discovered by Raychaudhuri et al. (U.S. Pat. No. 5,585,103), thecontents of which are hereby incorporated by reference in its entirety.The CTL inducing composition involves the use of an antigen formulationwhich has little or no toxicity to animals, and lacks animmunostimulating peptide (e.g., muramyl dipeptide), the presence ofwhich would decrease the desired response. More specifically, the CTLinducing composition (PROVAX™) comprises the antigen to which the CTLresponse is desired and a non-toxic antigen formulation which comprises,consists or consists essentially of a stabilizing detergent, amicelle-forming agent, and a biodegradable and biocompatible oil.

However, it has been documented that tumors escape from immunesurveillance by secreting factors or cytokines that exertimmunosuppressive effects on the functions of both activated andprecursor immune cells present locally and systemically. Therefore,cancer patients receiving therapeutic vaccines alone, vaccines which areaimed at enhancing the tumor immunity, may not fully benefit from suchvaccine.

Additionally, cancer patients, especially at late stages of the disease,show suppressed hematopoietic activity due to suppression of stem and/orprogenitor cells that are vital for the maintenance of healthy bonemarrow. This suppression is a result of compounding factors, includingradiation and chemotherapy which is used in cancer treatment as well asimmunosuppressive factors that may be upregulated by cancer treatments,such as, for example, transforming growth factor-β (TGFβ), a stablefamily of polypeptide growth factors which are secreted by normal aswell as the growing tumors of the host.

Therefore, in view of the aforementioned deficiencies attendant withpreviously known cancer vaccines and methods of treating tumors, itshould be apparent that there still exists a need in the art for moreefficient immunotherapeutic treatments and compositions.

SUMMARY OF THE INVENTION

The inventors of the present application have surprisingly discoveredthat the therapeutic efficacy of a vaccine which is aimed at enhancingtumor immunity, by induction of a CTL response can be increased whensuch CTL inducing vaccine is used in conjunction with one or more agentswhich are capable of neutralizing, antagonizing, down regulating orblocking tumor-secreted immunosuppressive factors, e.g., TGFβ and IL-10.

Accordingly, an object of the present invention is to provide acomposition comprising any adjuvant formulation capable of inducing CTLin combination with one or more agents which are capable ofneutralizing, blocking, antagonizing or down regulating the activity oftumor secreted factors. A particular preferred CTL inducing adjuvantcomprises the CTL inducing adjuvants disclosed in U.S. Pat. No.5,585,103, issued to Raychaudhuri et al., which comprise the following:an antigen to which an antigen-specific CTL response is to be inducedagonist and a microfluidized antigen formulation, said antigenformulation comprising:

(i) a stabilizing detergent,

(ii) a micelle-forming agent, and

(iii) a biodegradable and biocompatible oil,

and further wherein said antigen formulation lacks an immunostimulatingpeptide component and is formulated as a stable oil-in-water emulsion.Preferably the agent(s) which are capable of neutralizing, blocking,antagonizing or down regulating tumor-secreted immunosuppressive factorswill include anti-TGFβ antibodies, transforming growth factor-β receptorfusion proteins (TGFβR-fusion proteins), TGFβ antagonists such asthrombospondin peptides, TGFβ binding proteins and TGFβR blockingantibodies.

Another object of the present invention is to provide a method oftreatment which includes the induction of a CTL response wherein theimprovement comprises the use of an adjuvant which induces a CTLresponse and an antagonist of an immunosuppressive factor, preferablyTGFβ, said adjuvant and antagonist can be administered sequentially orconcurrently in either order.

A further object of the invention is to provide a method of treatingneoplastic or cancerous growths in a patient in need of such treatment.

An additional object of the present invention is to provide a method ofrestoring or boosting hematopoiesis in a patient.

With the foregoing and other objects, advantages and features of theinvention that will become hereinafter apparent, the nature of theinvention may be more clearly understood by reference to the followingdetailed description of the preferred embodiments of the invention andto the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 represents the antitumor activity of ovalalbumin/PROVAX™ and/oranti-TGFβ antibody treatment on established EG7 tumors.

FIGS. 2A and 2B represent the antitumor activity of E7/PROVAX™ and/oranti-TGFβ antibody treatment on HOPE2 cells.

FIGS. 3A and 3B represent the estimated level of the activated or latentforms of TGFβ-1 secreted by various cell lines after in vitro incubationin serum free medium (CHO-S SFM II, GIBCO, Cat. #91-0456) for 2 days(EL4; EG7 cells) or 5 days (3T3, KB and A431 cells) continuous cultureat 37° C.

FIG. 4 represents binding of monoclonal mouse anti-TGF-β1, β2, β3(Genzyme Corp: Cat. # 80-1835-03) for mouse or human TGFβ present inconditioned medium obtained from either human A431 cells or murineBALB/c 3t3 cells.

DETAILED DESCRIPTION OF THE INVENTION

As discussed supra, the inventors of the present application haveunexpectedly discovered that the therapeutic efficacy of a vaccine whichis aimed at enhancing tumor immunity, e.g., a CTL inducing adjuvant, isincreased when it is used in conjunction with one or more agents whichare capable of neutralizing or down regulating tumor secretedimmunosuppressive factors. The inventors have surprisingly discoveredthat this combination results in synergistic enhancement of cytotoxic Tlymphocyte response, thereby resulting in enhanced therapeutic responseagainst targeted antigen-expressing cells, e.g., a tumor. Additionally,the inventors have discovered that the use of one or more agents whichneutralize or down regulate the tumor secreted immunosuppressive factorsin combination with the vaccine or adjuvant assists in restoring orboosting hematopoiesis.

The soluble inhibitory or immunosuppressive factors or cytokines whichare secreted by tumor cells in order to avoid immune destructioninclude, for example, transforming growth factor β (TGFβ) (Mukherj etal., Curr. Opin. Oncol., 7:175 (1995)), interleukin 10 (IL-10) (Huber etal., J. Immunol., 148:277 (1992)), prostaglandin (PGE2) (Huang et al.,J. Immunol., 157:5512-20 (1996)), immunosuppressive acidic protein (IAP)(Yamaguchi et al., Oncology, 52:1-6 (1995)) and Lipocortin-1 (LC1)(Koseki et al., Surg. Today, 27:30-39 (1997)). TGFβ has been shown as atumor associated immunosuppressive molecule from studies done in theglioblastoma (Brooks et al., J. Exp. Medicine, 136:1631-47 (1972)).Ample evidence indicates that TGFβ is produced by a variety of humancancer cells, including breast carcinoma (Knabbe et al., Cell, 48:417-28(1987)), prostatic carcinoma (Ikeda et al., Biochemistry, 16:2406-10(1987)), colorectal carcinoma (Coffey et al., Cancer Res., 46:1164-69(1986)), endometrial carcinoma (Boyd et al., Cancer Res., 50:3394-99(1990)) and ovarian carcinoma (Wilson et al., P.R. Br. J. Cancer,63:102-08 (1991)).

TGFβ was originally identified by its ability to impart a transformedphenotype to normal fibroblasts and found to be produced by virtuallyall the cells (Wakefield et al., J. Cell. Biol., 105:965-75 (1987)). Inhumans, it is found in three different isoforms, TGFβ 1, 2 and 3. TGFβis a pleiotropic cytokine which affects a wide range of biologicalactivities, including immunosuppression, inflammation, hematopoiesis andwound repair (Sporn et al., Science, 233:532 (1986); Pallidino et al.,Ann. NY Acad. Sci., 593:181 (1990); Roberts et al., Adv. Cancer Res.,51:107 (1988).

Of particular relevance is the potent immunosuppressive activity of TGFβ(Pallidino et al., Ann. NY Acad. Sci., 593:181 (1990); Roberts et al.,Adv. Cancer Res., 51:107 (1988); Lucas et al., J. Immunol., 145:1415-22(1990)). TFGβ could exert immunosuppression by inhibiting, T and B cellproliferation (Kehrl et al., J. Exp. Med., 163:1037 (1986); Kehrl etal., J. Immunol., 137:3855 (1986); Kehrl et al., J. Immunol., 143:1868(1989)), LAK cell/CTL generation (Mulé et al., Cancer Immunol.Immunother., 26:9 (1988); Espevik et al., J. Immunol., 140:2312 (1988);Rook et al., J. Immunol, 136:3916 (1986); Ranges et al., J. Exp. Med.,166:991 (1987); Fontana et al., J. Immunol., 143:323 (1989); Susan etal., J. Exp. Med., 172:1777 (1990); Torre-Amione et al., PNAS, 87:1486(1990) and function, NK cell activity (Rook et al., J. Immunol.,136:3916 (1987); Susan et al., J. Exp. Med., 172:1777 (1990);Torre-Amione et al., PNAS, 87:1486 (1990)) macrophage oxygen metabolisms(Tsunawaki et al., Nature, 334:260 (1988)), IgG and IgM secretion (Kehrlet al., J. Immunol., 137:3855 (1986); Kehrl et al., J. Immunol.,143:1868 (1989) or by down regulating the Human Leukocyte Antigen(HLA-DR) (Czarniecki et al., J. Immunol., 140:4217 (1988); Zuber et al.,Eur. J. Immunol., 18:1623 (1988) and IL-2R (Kehrl et al., J. Exp. Med.,163:1037 (1986)).

Also of particular relevance is the affect TGFβ has on hematopoiesis.TGFβ has been shown to negatively regulate and even inhibit the growthof primitive hematopoietic cells (Sitnicka et al., Blood, 88(1):82-88(1996); Dybedal et al., Blood, 86(3):949-57 (1995)). Antagonist of TGFβcould, therefore, play an important role in improving established cancertherapies that are characterized by having dose-limiting myeloidsuppression. Suppression is a result of compounding factors which mayinclude both direct effects of the cancer therapeutics on hematopoiesisand indirect effects by upregulation of immunosuppressive factor. Forexample, Barcellos-Hoff et al., J. Clin. Invest., 93:892-99 (1994)demonstrated that ionizing radiation of mice leads to a rapid increasein levels of active TGFβ in mammary tissue and concomitant loss oflatent TGFβ.

The active form of TGFβ is a 25 kD homodimeric protein that issynthesized and secreted as a latent precursor form which becomes activepresumably upon enzymatic cleavage (Massague et al., Ann. Rev. Cell.Biol., 6:597-641 (1990)) although the exact method(s) of activation invivo have not as yet been elucidated. There is 70% similarity foundwithin each of the 3 major isoforms, TGFβ1, 2 and 3. Presumably, theactions of activated TGFβ are mediated via binding to various cellsurface receptors. At least 3 different TGFβ receptors, TGFβR-1, TGFβR-2and TGFβR-3 have been identified (Barnard et al., Biochim. Biophys.Acta, 1032:79-87 (1990)). All three receptors are type I integralmembrane glycoproteins and ubiquitously expressed by virtually all cellsin the body, except TGFβR-3 which is absent in monocytes. Both TGFβ andits receptors have been cloned and expressed. Other TGFβ membranebinding components have been described on fully differentiated subsetsof cells and are not ubiquitously expressed. In particular endoglin(CD105), primarily expressed on endothelial and pre-B cells, hasrecently been shown to bind TGFβ-1 and β3 isoforms (Zhang et al., J.Immunol., 156:565-573 (1996))

There have been various attempts to neutralize and/or down regulate theactivity of TGFβ. For example, antibodies which are specific for TGFβhave been suggested for use in treating tumor cells that produce TGFβ tocounteract the immunosuppressive effects of TGFβ (Segarini et al., WO94/09815). TGFβ-specific antibodies have also been found to restore orboost the growth of primitive hematopoietic cells, such as progenitorand stem cells, which were suppressed due to excess TGFβ production(Dybedal et al., Blood, 86(3):949-57 (1995); Sitnicka et al., Blood,88(1):82-88 (1996)).

A number of other strategies may be used to neutralize or down regulatethe active form of TGFβ. For example, TGFβ receptor (TGFβR) Fc-fusionproteins, especially the receptor II fusion proteins may be administeredto neutralize or down regulate TGFβ in vivo. Antibodies to TGFβ receptormay block the interaction of free TGFβ to the TGFβR and prevent downwardsignaling events in the target cell. Also, analogs of TGFβ or TGFβbinding proteins, e.g., thrombospondin peptides, could compete with freeTGFβ for the binding to the receptor and inactivate the receptor.Further, gene therapy approaches may be utilized in order to achieve theabove. Additional strategies have been described to prevent activationof TGFβ from its latent form which does not participate in signalingevents. For example, thrombospondin peptide sequences have beendescribed and synthesized which inhibit activation of latent TGFβ(Schultz-Cherry et al., J. Biol. Chem., 270:7304-7310 (1995)).

At least one agent capable of neutralizing or down regulating thebiological activity of tumor or host secreted immunosuppressive factorsis present in a therapeutically effective amount. In a preferredembodiment the agent is present in an amount ranging from about 5 toabout 1000 mg per square meter.

The CTL inducing composition involves the use of an antigen formulationwhich has little or no toxicity to animals, and lacks animmunostimulating peptide (e.g., muramyl dipeptide), the presence ofwhich would decrease the desired response. More specifically, the CTLinducing composition comprises the antigen to which the CTL response isdesired and a non-toxic antigen formulation which comprises, consists orconsists essentially of a stabilizing detergent, a micelle-formingagent, and a biodegradable and biocompatible oil. This antigenformulation preferably lacks any immunostimulating peptide component, orhas sufficiently low levels of such a component that the desiredcellular response is not diminished. This formulation is preferablyprovided as a stable microfluidized oil-in-water emulsion. That is, eachof the various components are chosen such that the emulsion will remainin an emulsion state for a period of at least one month, and preferablyfor more than one year, without phase separation. The antigen andantigen formulation are mixed together to form a mixture, and thatmixture can be administered to the animal in an amount sufficient toinduce CTL response in the animal.

By “non-toxic” is meant that little or no side effect of the antigenformulation is observed in the treated animal or human. Those ofordinary skill in the medical or veterinary arts will recognize thatthis term has a broad meaning. For example, in a substantially healthyanimal or human only slight toxicity may be tolerated, whereas in ahuman suffering from terminal disease (with a life expectancy of lessthan about three years) substantially more toxicity may be tolerated.

By “stabilizing detergent” is meant a detergent that allows thecomponents of the emulsion to remain as a stable emulsion. Suchdetergents include polysorbate 80 (TWEEN 80)(Sorbitan-mono-9-octadecenoate-poly(oxy)-1,2-ethanediyl; manufactured byICI Americas, Wilmington, Del.), TWEEN 40 (polyoxyethylenesorbitanmonopalmitate), TWEEN 20 (polyoxyethylenesorbitan monolaurate), TWEEN 60(polyoxyethylenesorbitan monostearate), ZWITTERGENT 3-12(N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate), TEEPOL HB7 (alkyl(C9-C13) sodium sulfates), and SPAN 85 (sorbitan trioleate). Thesedetergents are usually provided in an amount of approximately 0.05 to0.5%, preferably at about 0.2%.

By “micelle-forming agent” is meant an agent which is able to stabilizethe emulsion formed with the other components such that a micelle-likestructure is formed. Such agents preferably cause some irritation at thesite of injection in order to recruit macrophages to enhance thecellular response. Examples of such agents include PEG1000 (polyethyleneglycol having average molecular weight of 1000), and block polymersurfactants such as those described by BASF Wyandotte publications,e.g., Schmolka, J. Am. Oil. Chem. Soc., 54:110 (1977) and Hunter et al.,J. Immunol., 127(3):1244 (1981), both hereby incorporated by reference.Such surfactants are called block polymers because they containpolyoxypropylene (POP) and polyoxyethylene (POE) portions which occur inseparate blocks, and include PLURONIC L62LF, L101, and L64, L121(poloxamer 401), and TETRONIC 1501, 150R1, 701, 901, 1301, and 130R1.The chemical structures of such agents are well known in the art. Forexample, PLURONIC L121 (poloxamer 401) has the general structure:(POE)_(a)-(POP)_(b)-(POE)_(a), as shown below:

wherein a and b are such that the average molecular weight of thepolyoxypropylene blocks in the molecule is 4000, and approximately 10%of the molecular weight of the copolymer is composed of thepolyoxyethylene blocks. Preferably, the agent is chosen to have ahydrophile-lipophile balance (HLB) of between 0 and 2, as defined byHunter and Bennett, Journal of Immunology, 133:3167 (1984). The agent ispreferably provided in an amount between 0.001 and 10%, most preferablyin an amount between 0.001 and 5%.

The oil is chosen to promote the retention of the antigen inoil-in-water emulsion, i.e., to provide a vehicle for the desiredantigen, and preferably has a melting temperature of less than 65° C.such that emulsion is formed either at room temperature (about 20° C. to25° C.), or once the temperature of the emulsion is brought down to roomtemperature. Examples of such oils include squalene, Squalane, EICOSANE,tetratetracontane, glycerol, and peanut oil or other vegetable oils. Theoil is preferably provided in an amount between 1 and 10%, mostpreferably between 2.5 and 5%. It is important that the oil isbiodegradable and biocompatible so that the body can break down the oilover time, and so that no adverse affects, such as granulomas, areevident upon use of the oil.

It is important in the above formulation that a peptide component,especially a muramyl dipeptide (MDP) be lacking. Such a peptide willinterfere with induction of a CTL response if it provided in an amountgreater than about 20 micrograms per normal human formulationadministration. It is preferred that such peptides are completely absentfrom the antigen formulation, despite their apparent stimulation of thehumoral compartment of the immune system. That is, although suchpeptides may enhance the humoral response, they are disadvantageous whena cytotoxic T-lymphocyte response is desired.

The antigen formulation can be formed from only two of the above threecomponents and used with any desired antigen (which term includesproteins, polypeptides, and fragments thereof which are immunogenic), toinduce a CTL response in the above animals or humans.

In preferred embodiments, the method consists essentially of a singleadministration of the mixture (antigen plus antigen formulation) to thehuman or the animal; the human or animal is infected with a cancer orvirus and suffers one or more symptoms (as generally defined by medicaldoctors in the relevant field) of infection from the cancer or virus;and the antigen formulation is non-toxic to the human or animal.

In other preferred embodiments, the antigen is chosen from melanocyticdifferentiation antigens, for example: gp100 (Kawakami et al., J.Immunol. 154:3961-3968 (1995); Cox et al., Science, 264:716-719 (1994)),MART-1/Melan A (Kawakami et al., J. Exp. Med., 180:347-352 (1994);Castelli et al., J. Exp. Med., 181:363-368 (1995)), gp75 (TRP-1) (Wanget al., J. Exp. Med., 186:1131-1140 (1996)), and Tyrosinase (Wolfel etal., Eur. J. Immunol., 24:759-764 (1994); Topalian et al., J. Exp. Med.,183:1965-1971 (1996)); melanoma proteoglycan (Hellstrom et al., J.Immunol., 130:1467-1472 (1983); Ross et al., Arch. Biochem Biophys.,225:370-383 (1983)); tumor-specific, widely shared antigens, forexample: antigens of MAGE family, for example, MAGE-1, 2, 3, 4, 6, and12 (Van der Bruggen et al., Science, 254:1643-1647 (1991); Rogner etal., Genomics, 29:729-731 (1995)), antigens of BAGE family (Boel et al.,Immunity, 2:167-175 (1995)), antigens of GAGE family, for example,GAGE-1,2 (Van den Eynde et al., J. Exp. Med., 182:689-698 (1995)),antigens of RAGE family, for example, RAGE-1 (Gaugler et al.,Immunogenetics, 44:323-330 (1996)), N-acetylglucosaminyltransferase-V(Guilloux et al., J. Exp. Med., 183:1173-1183 (1996)), and p15 (Robbinset al., J. Immunol., 154:5944-5950 (1995)); tumor specific mutatedantigens; mutated β-catenin (Robbins et al., J. Exp. Med., 183:1185-1192(1996)), mutated MUM-1 (Coulie et al., Proc. Natl. Acad. Sci. USA,92:7976-7980 (1995)), and mutated cyclin dependent kinases-4 (CDK4)(Wolfel et al., Science, 269:1281-1284 (1995)); mutated oncogeneproducts: p21 ras (Fossum et al., Int. J. Cancer, 56:40-45 (1994)),BCR-abl (Bocchia et al., Blood, 85:2680-2684 (1995)), p53 (Theobald etal., Proc, Natl. Acad. Sci. USA, 92:11993-11997 (1995)), and p185HER2/neu (Fisk et al., J. Exp. Med., 181:2109-2117 (1995)); Peoples etal., Proc. Natl. Acad. Sci., USA, 92:432-436 (1995)); mutated epidermalgrowth factor receptor (EGFR) (Fujimoto et al., Eur. J. Gynecol. Oncol.,16:40-47 (1995)); Harris et al., Breast Cancer Res. Treat, 29:1-2(1994)); carcinoembryonic antigens (CEA) (Kwong et al., J. Natl. CancerInst., 85:982-990 (1995)); carcinoma associated mutated mucins, forexample, MUC-1 gene products (Jerome et al., J. Immunol., 151:1654-1662(1993), Ioannides et al., J. Immunol., 151:3693-3703 (1993), Takahashiet al., J. Immunol., 153:2102-2109 (1994)); EBNA gene products of EBV,for example, EBNA-1 gene product (Rickinson et al., Cancer Surveys,13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing etal., J. Immunol., 154:5934-5943 (1995)); prostate specific antigens(PSA) (Xue et al., The Prostate, 30:73-78 (1997)); prostate specificmembrane antigen (PSMA) (Israeli, et al., Cancer Res., 54:1807-1811(1994)); PCTA-1 (Sue et al., Proc. Natl. Acad. Sci. USA, 93:7252-7257(1996)); idiotypic epitopes or antigens, for example, immunoglobulinidiotypes or T cell receptor idiotypes, (Chen et al., J. Immunol.,153:4775-4787 (1994); Syrengelas et al., Nat. Med., 2:1038-1040 (1996));antigens of HIV: gp160, gag, pol, nef, Tat and Rev; the malariaantigens: CS protein and Sporozoite surface protein 2; the Hepatitis Bsurface antigens: Pre-S1, Pre-S2, HBc Ag, and HBe Ag; the influenzaviral antigens: HA, NP and NA; Hepatitis A surface antigens; Hepatitis Csurface antigens; the Herpes virus antigens: HSV gB, HSV gD, HSV gH, HSVearly protein product, human papillomavirus antigens, cytomegalovirusgB, cytomegalovirus gH and IE protein gp72; respiratory syncytial virusantigens: F protein, G protein and N protein.

The CTL inducing adjuvant can be combined with the agent which iscapable of neutralizing, blocking, antagonizing or down regulating theactivity of tumor secreted immunosuppressive factors and administered tothe patient as a single composition or the two components can beadministered separately. Administration can be achieved via numerouswell known techniques. Such modes of administration include, forexample, intradermal injection, subcutaneous injection, intraperitonealinjection, and intramuscular injection. Furthermore, administration ofagents capable of neutralizing or down regulating immunosuppressivemolecules can be administered separately independent of adjuvantadministration, for example intravenously or intraperitoneally. Thepreferred embodiment is to administer the antigen containing CTLinducing adjuvant formulation intradermally, intramuscularly orsubcutaneously and the neutralizing agent systemically via intravenousadministration.

Synergism should be observed in any disease condition whereimmunosuppressive factors such as TGFβ have an adverse effect on thehost's ability in being able to elicit a therapeutic CTL response. Suchdiseases include by way of example many cancers and neoplastic growths,viral infections and parasitic infections. Cancers which can be treatedusing the subject synergistic combination include, by way of example,breast cancer, brain cancer, cervical cancer, leukemia, lymphoma,prostate cancer, skin cancer, colon cancer, lung cancer, ovarian cancer,pancreatic cancer, liver cancer, bladder cancer, kidney cancer, myeloma,colorectal cancer, nasoparingeal carcinoma and endometrial cancer. Viraland parasitic infections treatable according the invention include, forexample, papillomavirus, malaria, Hepatitis, Herpes, cytomegalovirus,respiratory syncytial virus and HIV. As discussed above, anotherimportant aspect of the invention includes the induction ofhematopoiesis. This is of significant therapeutic importance in, forexample, cancer therapies.

In this regard, it is well known that cancer patients, especially atlate stages of the disease, show suppressed hematopoietic activity dueto suppression of stem or progenitor cells. This suppression is a resultof factors such as radiation and chemotherapy which is used in cancertreatment as well as immunosuppressive factors which are secreted bytumors. Treatment with the inventive combination composition allowshematopoiesis to be restored or boosted. Moreover, it should furtherimprove chemo or radio therapy as it should enable the therapeuticdosages to be administered without adverse effects.

The following examples are presented in order to more fully illustratethe preferred embodiments of the invention. They should in no way beconstrued, however, as limiting the broad scope of the invention.

EXAMPLES Example 1

Mice were inoculated with ovalbumin expressing EG7 cells (2×10⁶cells/mouse). Derivation of EG7 is described previously by Moore et al.,Cell, 54:777 (1988). On day 7, post-inoculation mice bearing 250-350 mm³size tumors were sorted in to 5 groups and treated as follows: Group A,the control group received no antigen injection (▪), Group B received 30μg of ovalbumin in PROVAX s.c. (●), Group C received 30 μg ovalbumin inPROVAX™ s.c. and 50 μg of anti-TGFβ antibodies i.p. per mouse (▴), andGroup D received 50 μg of anti-TGFβ antibodies i.p. (Δ). The data as setforth in FIG. 1 indicates that the treatment of mice bearingprogressively growing EG7 tumors with anti-TGFβ antibodies inconjunction with ovalbumin in PROVAX™ gave enhanced anti-tumor activityunder conditions where treatment with ovalbumin-PROVAX™ is noteffective.

Example 2

Mice were inoculated with HPV-E7 expressing HOPE2 cells (4×10⁶ cellsmouse) (2.A.). E7 expressing HOPE2 transfectant was obtained byelectroporation of an E7 encoding mammalian expression plasmid intoK1735-X21 cells (Kind gift from Dr. Isaiah J. Fidler). The HumanPapillomavirus Type 16 E7 expression vector, INPEP4+LE7, contains a 300bp E7 encoding fragment (amino acid residues 2-97; Seedorf et al.,Virology, 145:181-185 (1985)) fused downstream of an immuglobulin leadersequence (L). Transcription is driven by the Cytomegaloviruspromoter/enhancer (CMV) and the bovine growth hormone (BGH) 3′ flankingsequence provides a polyadenylation signal for RNA processing. Bacterialneomycin phosphotransferase (N) and mammalian dihydrofolate reductase(DHFR) expression cassettes, driven by the mouse beta-globin majorpromoter (BETA), allow dominant selection by G418 and methotrexate,respectively. The neomycin gene cassette includes the SV40 earlypolyadenylation signal (SV40) for RNA processing. Plasmid DNA islinearized by restriction digestion with PAC I prior to electroporation.K1735-X21 cells were grown in MEM Alpha medium (Gibco BRL.) supplementedto 10% (v/v) non-essential amino acids (Irvine Sci.), 10% (v/v)L-glutamine (Irvine Sci.), 20% (v/v) MEM Vitamin solution (Gibco BRL.),1 mM Sodium Pyruvate (Biowhittaker), and 5% FBS (Gibco BRL.). 1 μg ofPac I linearized INPEP4+LE7 DNA was electroporated into 4×10⁶ K1735-X21cells and using a BTX 600 Electroporator (375 volts, 13 ohms, and 25microfaradays). The cells were plated in a 96 well flat bottom plate.After 24 hours of incubation, the cells were fed by media supplementedwith 0.4 mg/ml active G418. G418 resistant clones were screened for E7expression by ELISA, Western and Northern blot analyses and selected forfurther expansion. HOPE2 was positive for E7 expression by all of theabove analyses.

On day 11 post-inoculation, mice bearing 75-150 mm³ size tumors weresorted in to 4 groups and treated as follows: Group A, the control groupreceived no antigen injection (□), Group B received 30 μg of E7 inPROVAX™ s.c. (⋄), Group C received 30 μg ovalbumin in PROVAX™ s.c. and100 μg of anti-TGFβ antibodies i.p. per mouse (Δ) and Group D receivedsingle i.p. injection of 100 μg of anti-TGFβ antibodies (◯). The data asset forth in FIG. 2A indicates that the treatment of mice bearingprogressively growing HOPE2 tumors with anti-TGFβ antibodies inconjunction with E7-PROVAX™ gave enhanced anti-tumor activity.

In another experiment, on day 13 post HOPE2 inoculation, mice weresorted and grouped as above. These groups of mice were treated similarto 2.A., except for Group C (Δ) and D (◯), which received 4 injectionsof anti-TGFβ antibodies every 4 days between day 15-29 (2.B.). Theresults are set forth in FIG. 2B.

While the invention has been described and illustrated herein byreferences to various specific material, procedures and examples, it isunderstood that the invention is not restricted to the particularmaterial, combinations of material, and procedures selected for thatpurpose. Numerous variations of such details can be implied and will beappreciated by those skilled in the art. Furthermore, all of thepublications, patents and patent applications cited herein areincorporated by reference in their entirety.

Example 3

The concentration of TGFβ1 secreted by murine cell lines 3T3 (BALB/corigin), HOPE2 (C3H origin) EL4, and EG7 (C57BL/6) and human cell linesKB (epidermoid carcinoma ATCC # CCL-17) and A431 (epidermoid carcinoma,ATCC # CRL-1555) were measured by TGFβ1 ELISA kit (Genzyme Corp., Cat. #80-3108). FIGS. 3A and 3B measure the TGFβ1 concentration from serumfree conditioned medium (CM) using GIBCO CHO-S SFM II (Cat. # 91-0456)after either 3 days (Cell Lines EL4 and EG7) or 5 days (KB, A431 andHOPE2) of continuous culture in vitro at 37° C. CM was centrifuged at400×g for 5 minutes before analyzing for TGFβ concentration as permanufactures instructions

FIG. 3A measures the activity of CM directly (fully active TGFβ1) andafter acid activation followed by neutralization according tomanufacturers instructions (total TGFβ1). The fraction of latent TGFβ1in CM was estimated by subtracting the active concentration of TGFβ fromthe total TGFβ concentration. As shown in FIG. 3A all cell linesincubated in vitro secreted TGFβ1, and ≧98% of the secreted material wasin the latent form.

FIG. 3B estimates the level of TGFβ1 in conditioned medium from thevarious cell lines after normalization for the total cell number presentafter the 2 or 5 days incubation at 37° C.

Example 4

FIG. 4 demonstrates the binding activity of the anti-TGFβ neutralizingantibody for either murine or human TFGβ, after acid activation andneutralization according to manufactures instructions. Murine TGFβ wasobtained from BALB/c 3T3 conditioned medium (see FIG. 3) and dilutedwith PBS to 0.2 ng/ml, and human TGFβ was obtained from A431 CM anddiluted with PBS to 0.4 ng/ml. Conditioned medium was incubated withvarious dilutions of monoclonal mouse anti-TGF-β1, β2, β3 (Genzyme Corp:Cat. # 80-1835-03) for 3 hours at 4° C. and assayed for unconjugatedTGFβ using the ELISA assay described in FIG. 3. The anti-TGFβneutralizing antibody shows comparable binding to TGFβ from both humanand murine sources.

1-37. (canceled)
 38. A method of treating infection by a viruscomprising administering to a patient in need thereof: (a) an admixturecomprising a viral antigen expressed by cells infected by said virus anda microfluidized antigen formulation comprising: (i) a stabilizingdetergent, (ii) a micelle-forming agent, and (iii) a biodegradable andbiocompatible oil, said antigen formulation being formulated as a stableoil-in-water emulsion; wherein said admixture is administered to saidpatient in an amount sufficient to induce a cytotoxic T-lymphocyteresponse in said patient which is specific for the viral antigencontained in said admixture, and (b) a therapeutically effective amountof at least one agent which is capable of neutralizing, blocking,antagonizing, or down regulating the activity or preventing activationof transforming growth factor β (TGFβ) specifically, which agent isselected from the group consisting of an anti-TGFβ antibody, aTGFβR-fusion protein, a TGFβ analog, a TGFβ binding protein, and a TGFβRblocking antibody; wherein the antigen-containing admixture and the atleast one agent which is capable of neutralizing, blocking,antagonizing, or down regulating the activity or preventing activationof TGFβ are administered sequentially or concurrently, and in any order.39. The method of claim 38, wherein the antigen-containing admixture andthe at least one agent which is capable of neutralizing, blocking,antagonizing, or down regulating the activity or preventing activationof TGFβ are administered sequentially.
 40. The method of claim 38,wherein the antigen-containing admixture is administered intradermally,intramuscularly or subcutaneously and the at least one agent which iscapable of neutralizing, blocking, antagonizing, or down regulating theactivity or preventing activation of TGFβ is administered intravenously.41. The method of claim 38, wherein the at least one agent which iscapable of neutralizing, blocking, antagonizing, or down regulating theactivity or preventing activation of TGFβ is a thrombospondin peptide ora TGFβR Fc-fusion protein.
 42. The method of claim 38, wherein the virusis selected from the group consisting of Epstein Barr virus (EBV), humanpapillomavirus (HPV), human immunodeficiency virus (HIV), influenzavirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Herpesvirus (HSV), cytomegalovirus, and respiratory syncytial virus.
 43. Themethod of claim 42, wherein the admixture comprises a viral antigenselected from the group consisting of EBNA gene products of EBV; E6protein of HPV; E7 protein of HPV, gp160 protein of HIV, gag protein ofHIV, pol protein of HIV, nef protein of HIV, Tat protein of HIV, Revprotein of HIV, surface antigenic proteins of Hepatitis A virus, Pre-S1protein of Hepatitis B virus, Pre-S2 protein of Hepatitis B virus, HBcAg protein of Hepatitis B virus, HBe Ag protein of Hepatitis B virus,surface antigenic proteins of Hepatitis C virus, HA protein of influenzavirus, NP protein of influenza virus, NA protein of influenza virus, gBprotein of HSV, gD protein of HSV, gH protein of HSV, early proteinproduct of HSV, gB protein of cytomegalovirus, gH protein ofcytomegalovirus, IE protein gp72 of cytomegalovirus, F protein ofrespiratory syncytial virus, G protein of respiratory syncytial virus,and N protein of respiratory syncytial virus.
 44. The method of claim38, wherein the detergent is provided in an amount ranging fromapproximately 0.05 to 0.5%.
 45. The method of claim 38, wherein theamount of detergent is about 0.2%.
 46. The method of claim 38, whereinthe detergent is selected from the group consisting ofsorbitan-mono-9-octadecenoate-poly(oxy)-1,2-ethanediyl,polyoxyethylene-sorbitan monolaurate, polyoxyethylenesorbitanmonopalmitate, polyoxyethylenesorbitan monostearate,N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, alkyl (C₉-C₁₃)sodium sulfates, and sorbitan trioleate.
 47. The method of claim 38,wherein the micelle-forming agent has a hydrophile-lipophile balance ofbetween 0 and
 2. 48. The method of claim 38, wherein the amount of themicelle-forming agent ranges from 0.5 to 10%.
 49. The method of claim48, wherein the amount of the micelle-forming agent ranges from 1.25 to5%.
 50. The method of claim 38, wherein the amount of oil ranges from 1to 10%.
 51. The method of claim 50, wherein the amount of oil rangesfrom 2.5 to 5%.
 52. The method of claim 38, wherein the oil exhibits amelting temperature of less than 65° C.
 53. The method of claim 38,wherein the oil is selected from the group consisting of squalane,eicosane, tetratetracontane, pristane, and vegetable oils.
 54. Themethod of claim 38, wherein the antigen-containing admixture comprisessorbitan-mono-9-octadecenoate-poly(oxy)-1,2-ethanediyl, a blockcopolymer having the structure:

wherein a and b are such that the average molecular weight of thepolyoxypropylene blocks in the molecule is 4000 and approximately 10% ofthe molecular weight of the copolymer is composed of the polyoxyethyleneblocks, and squalane.
 55. The method of claim 38, wherein theantigen-containing admixture contains no more than 20 micrograms of animmunostimulating muramyl dipeptide.
 56. The method of claim 38, whereinthe antigen-containing admixture lacks an immunostimulating muramyldipeptide.